|
|
Volumn 134, Issue 12, 2007, Pages 949-956
|
|
Other immunosuppressants: Azathioprine (Imurel®), mycophenolate mofetil (Cellcept®), cyclophosphamide (Endoxan®);Autres immunosuppresseurs: Azathioprine (Imurel®), mycophénolate mofétil (Cellcept®), cyclophosphamide (Endoxan®)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACICLOVIR;
ACROLEIN;
ALLOPURINOL;
AMIODARONE;
ANTACID AGENT;
ANTHRACYCLINE;
ANTICOAGULANT AGENT;
AZATHIOPRINE;
COLESTYRAMINE;
CORTICOSTEROID DERIVATIVE;
COTRIMOXAZOLE;
CYCLOPHOSPHAMIDE;
CYCLOSPORIN;
IMMUNOSUPPRESSIVE AGENT;
IRON;
LIVE VACCINE;
MESNA;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PHENYTOIN;
SULFALAZINE;
TACROLIMUS;
WARFARIN;
YELLOW FEVER VACCINE;
DRUG DERIVATIVE;
MYCOPHENOLIC ACID;
ABDOMINAL PAIN;
ACNE FULMINANS;
AGITATION;
ALOPECIA;
AMENORRHEA;
ANEMIA;
ANOREXIA;
ANXIETY;
ARTHRALGIA;
ARTICLE;
ATOPIC DERMATITIS;
AZOOSPERMIA;
BACTERIAL INFECTION;
BEHCET DISEASE;
BLEEDING;
BONE MARROW SUPPRESSION;
CARCINOMA;
CARDIAC GRAFT REJECTION;
CARDIOMYOPATHY;
CHOLESTASIS;
CONTACT DERMATITIS;
CONVULSION;
CYTOLYSIS;
CYTOMEGALOVIRUS INFECTION;
DEPRESSION;
DERMATOMYOSITIS;
DIARRHEA;
DISCOID LUPUS ERYTHEMATOSUS;
DOSE RESPONSE;
DRUG ABSORPTION;
DRUG COST;
DRUG EFFECT;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG FORMULATION;
DRUG HYPERSENSITIVITY;
DRUG INDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG MONITORING;
DRUG STORAGE;
DYSHIDROSIS;
DYSURIA;
ECCHYMOSIS;
ECZEMA;
EPIDERMOLYSIS BULLOSA ACQUISITA;
ERYTHEMA;
FATIGUE;
FETUS MALFORMATION;
HEMATURIA;
HEMORRHAGIC CYSTITIS;
HERPES SIMPLEX;
HERPES ZOSTER;
HISTIOCYTOSIS;
HUMAN;
HYPERPIGMENTATION;
HYPOTENSION;
IMMUNOSUPPRESSIVE TREATMENT;
INAPPROPRIATE VASOPRESSIN SECRETION;
INSOMNIA;
INTERSTITIAL PNEUMONIA;
KAPOSI SARCOMA;
KIDNEY CARCINOMA;
KIDNEY DISEASE;
KIDNEY FAILURE;
KIDNEY GRAFT REJECTION;
LEUKOPENIA;
LICHEN PLANUS;
LIVER GRAFT REJECTION;
LIVER METABOLISM;
LIVER TOXICITY;
LUNG FIBROSIS;
LUPUS ERYTHEMATOSUS;
LYMPHOCYTOPENIA;
LYMPHOMA;
MALAISE;
MEGALOCYTOSIS;
MOUTH ULCER;
NAUSEA;
NECROBIOSIS LIPOIDICA;
NECROSIS;
NECROTIZING ARTERITIS;
NEUTROPENIA;
PANCREATITIS;
PEMPHIGOID;
PEMPHIGUS;
PEMPHIGUS VULGARIS;
PHOTODERMATOSIS;
PITYRIASIS;
PNEUMONIA;
POLLAKISURIA;
POLYARTERITIS NODOSA;
POLYMYOSITIS;
PRURIGO;
PSORIASIS;
PYODERMA GANGRENOSUM;
PYURIA;
RELAPSING POLYCHONDRITIS;
RETICULOHISTIOCYTOSIS;
RHABDOMYOLYSIS;
SARCOIDOSIS;
SCLEROMYXEDEMA;
SIDE EFFECT;
SKIN CANCER;
SKIN DISEASE;
SKIN LUPUS ERYTHEMATOSUS;
SKIN LYMPHOMA;
SOMNOLENCE;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TERATOGENICITY;
THROMBOCYTOPENIA;
TOXIC EPIDERMAL NECROLYSIS;
TREATMENT DURATION;
URINARY EXCRETION;
URTICARIA;
UTERUS CANCER;
VASCULITIS;
VERTIGO;
VIRUS INFECTION;
VISUAL DISORDER;
VOMITING;
VULVA CANCER;
WART VIRUS;
WEAKNESS;
WEGENER GRANULOMATOSIS;
AZATHIOPRINE;
CYCLOPHOSPHAMIDE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MYCOPHENOLIC ACID;
SKIN DISEASES;
|
|
EID: 38049186822
PISSN: 01519638
EISSN: None
Source Type: Journal
DOI: 10.1016/S0151-9638(07)78256-X Document Type: Article |
|
Times cited : (1)
|
|
References (6)
|
